title: IVIG trials in MS. Is albumin a placebo?
authors.forename: Otto R
authors.initials: OR
authors.lastname: Hommes
authors.forename: Judith
authors.initials: J
authors.lastname: Haas
authors.forename: Per
authors.initials: P
authors.lastname: Soelberg-Sorenson
authors.forename: Mieke
authors.initials: M
authors.lastname: Friedrichs
mesh_terms: D000418:Albumins / Q000276:immunology / Q000494:pharmacology*; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D018450:Disease Progression; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D015990:Placebo Effect; D010919:Placebos / Q000494:pharmacology*; D055502:Secondary Prevention; D012965:Sodium Chloride / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000418:Albumins; D016756:Immunoglobulins, Intravenous; D010919:Placebos; D012965:Sodium Chloride